Open justaddcoffee opened 2 years ago
Discussing this more with Harry - some thoughts.
We can use NEAT for this (i.e. spin up a Google Cloud instance from Jenkins, pass off a YAML file to the instance describing the graph ML task, wait for it to complete and upload artifacts to S3).
This strategy has the advantage of:
As per IDG meeting on Jan 20, following drug categories would be good for evaluation:
I don't think we include any viral proteins right now, so we'd expect the antivirals to have few/no human targets, especially because we aren't doing any inference based off sequence or structure.
Describe the desired behavior
It would be useful for Drug Central to have inferred drug -> drug target edges, which we could formulate as a graph ML link prediction task.
We maybe could/should do this in an automated way, on each build of KG-IDG.
A possible roadmap:
Additional context
Per convo with Tudor et al on IDG just now